Tosteson A N A, Melton L J, Dawson-Hughes B, Baim S, Favus M J, Khosla S, Lindsay R L
Multidisciplinary Clinical Research Center in Musculoskeletal Diseases and The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Medical School, Lebanon, NH 03756, USA.
Osteoporos Int. 2008 Apr;19(4):437-47. doi: 10.1007/s00198-007-0550-6. Epub 2008 Feb 22.
A United States-specific cost-effectiveness analysis, which incorporated the cost and health consequences of clinical fractures of the hip, spine, forearm, shoulder, rib, pelvis and lower leg, was undertaken to identify the 10-year hip fracture probability required for osteoporosis treatment to be cost-effective for cohorts defined by age, sex, and race/ethnicity. A 3% 10-year risk of hip fracture was generally required for osteoporosis treatment to cost less than $60,000 per QALY gained.
Rapid growth of the elderly United States population will result in so many at risk of osteoporosis that economically efficient approaches to osteoporosis care warrant consideration.
A Markov-cohort model of annual United States age-specific incidence of clinical hip, spine, forearm, shoulder, rib, pelvis and lower leg fractures, costs (2005 US dollars), and quality-adjusted life years (QALYs) was used to assess the cost-effectiveness of osteoporosis treatment ($600/yr drug cost for 5 years with 35% fracture reduction) by gender and race/ethnicity groups. To determine the 10-year hip fracture probability at which treatment became cost-effective, average annual age-specific probabilities for all fractures were multiplied by a relative risk (RR) that was systematically varied from 0 to 10 until a cost of $60,000 per QALY gained was observed for treatment relative to no intervention.
Osteoporosis treatment was cost-effective when the 10-year hip fracture probability reached approximately 3%. Although the RR at which treatment became cost-effective varied markedly between genders and by race/ethnicity, the absolute 10-year hip fracture probability at which intervention became cost-effective was similar across race/ethnicity groups, but tended to be slightly higher for men than for women.
Application of the WHO risk prediction algorithm to identify individuals with a 3% 10-year hip fracture probability may facilitate efficient osteoporosis treatment.
进行了一项针对美国的成本效益分析,该分析纳入了髋部、脊柱、前臂、肩部、肋骨、骨盆和小腿临床骨折的成本及健康后果,以确定对于按年龄、性别和种族/族裔划分的队列而言,骨质疏松症治疗具有成本效益所需的10年髋部骨折概率。骨质疏松症治疗每获得一个质量调整生命年(QALY)的成本低于60,000美元时,通常需要10年髋部骨折风险达到3%。
美国老年人口的快速增长将导致大量有骨质疏松症风险的人群,因此需要考虑经济有效的骨质疏松症护理方法。
使用一个马尔可夫队列模型,该模型包含美国每年特定年龄的髋部、脊柱、前臂、肩部、肋骨、骨盆和小腿临床骨折发病率、成本(2005年美元)以及质量调整生命年(QALY),以评估按性别和种族/族裔分组的骨质疏松症治疗(5年每年药物成本600美元,骨折风险降低35%)的成本效益。为了确定治疗具有成本效益时的10年髋部骨折概率,将所有骨折的平均每年特定年龄概率乘以一个相对风险(RR),该相对风险从0到10系统地变化,直到观察到相对于不进行干预,治疗每获得一个QALY的成本为60,000美元。
当10年髋部骨折概率达到约3%时,骨质疏松症治疗具有成本效益。尽管治疗变得具有成本效益时的RR在性别和种族/族裔之间有显著差异,但干预变得具有成本效益时的绝对10年髋部骨折概率在各种族/族裔群体中相似,但男性往往略高于女性。
应用世界卫生组织风险预测算法识别10年髋部骨折概率为3%的个体可能有助于高效的骨质疏松症治疗。